A photoreactive peptide that binds antibody Fc regions enables site-specific attachment of exactly two drug molecules to trastuzumab using light and click chemistry.
DAR 2 achievedExactly 2 drugs per antibody via site-specific photoconjugation at Glu-382
What the researchers found
A photoreactive Fc-binding peptide achieved site-specific conjugation to trastuzumab at Glu-382, enabling precise DAR 2 antibody-drug conjugate formation via click chemistry.
Why it matters
Current ADCs attach drugs randomly to antibodies, creating inconsistent products. Site-specific conjugation improves manufacturing reproducibility, drug-to-antibody ratio control, and potentially efficacy.
The numbers in context
Site-specific at Glu-382; DAR 2; photoreactive Fc-binding peptide; click chemistry drug attachment
How the study worked
Peptide chemistry and bioconjugation: designed high-affinity IgG Fc-binding peptide with photoreactive amino acid, UV-activated conjugation to trastuzumab, then click chemistry for drug attachment. Product characterized for DAR.
Who was studied
Trastuzumab antibody (in vitro conjugation chemistry)
What this study cannot tell us
Chemistry proof-of-concept only — no cell killing or in vivo efficacy data; only tested on trastuzumab; scalability of photoconjugation not assessed.
How to read the evidence
Preliminary — chemistry proof-of-concept without biological activity data.
When this study was published
Published in 2020; ADC technology and site-specific conjugation methods have continued to advance rapidly.
The bigger picture
ADCs are one of the fastest-growing cancer drug classes (B+ market). Better conjugation chemistry means more uniform products, simpler manufacturing, and potentially improved patient outcomes.
Questions still open
- Does site-specific DAR 2 conjugation improve anti-tumor efficacy compared to random conjugation ADCs?
- Can this approach work with other therapeutic antibodies beyond trastuzumab?
- Is UV-activated conjugation practical at manufacturing scale?
Common questions
What is an antibody-drug conjugate?
Why does it matter where the drug attaches?
Read the original research
Photoconjugation of an Fc-Specific Peptide Enables Efficient DAR 2 Antibody-Drug Conjugate Formation.
Organic letters, 22(21), 8419-8423
Citation
Lee, TaeJin; Kim, Ju Hwan; Kwon, Se Jeong; Park, Sun Hee; Kim, Jinyoung; Kang, Hyo Jin; Chung, Sang J. (2020). Photoconjugation of an Fc-Specific Peptide Enables Efficient DAR 2 Antibody-Drug Conjugate Formation.. Organic letters, 22(21), 8419-8423. https://doi.org/10.1021/acs.orglett.0c03049